Therapeutic potential of a reduced-intensity preparative regimen for allogeneic transplantation with cladribine, busulfan, and antithymocyte globulin against advanced/refractory acute leukemia/lymphoma

Clinical Cancer Research

Volumn 8, Issue 4, 2002, Pages 1014-1020

  Saito, Takeshi ^a   Kanda, Yoshinobu ^a   Kami, Masahiro ^a   Kato, Kazunori ^b   Shoji, Nahoko ^a   Kanai, Sachiyo ^b,c   Ohnishi, Toshihiro ^c   Kawano, Yoshifumi ^c,d   Nakai, Kunihisa ^a   Ogasawara, Toshie ^a   Matsubara, Hiroshi ^a   Makimoto, Atsushi ^a   Tanosaki, Ryuji ^a   Tobinai, Kensei ^a   Wakasugi, Hiro ^b   Takaue, Yoichi ^a   Mineishi, Shin ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^c UNIVERSITY OF TOKUSHIMA   (Japan)

^d NATIONAL KYUSHU CANCER CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CLADRIBINE; IMTIX; THYMOCYTE ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ADULT; ADVANCED CANCER; AGED; ARTICLE; BACTEREMIA; BRAIN INFARCTION; CANCER RECURRENCE; CANCER SURVIVAL; CANDIDIASIS; CHIMERA; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; DRUG TOLERABILITY; FEMALE; GRAFT VERSUS HOST REACTION; HIGH RISK PATIENT; HUMAN; LYMPHOMA; MALE; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; STOMATITIS; T LYMPHOCYTE;

ADOLESCENT; ADULT; AGED; ANTILYMPHOCYTE SERUM; BUSULFAN; CLADRIBINE; COMBINED MODALITY THERAPY; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKEMIA, MYELOCYTIC, ACUTE; LEUKEMIA, MYELOID, CHRONIC; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PILOT PROJECTS; STAPHYLOCOCCAL INFECTIONS; SURVIVAL ANALYSIS; TRANSPLANTATION CHIMERA; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 0036554818     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Carella, A. M., Champlin, R., Slavin, S., McSweeney, P., and Storb, R. Mini-allografts: ongoing trials in humans. Bone Marrow Transplant., 25: 345-350, 2000.
2. Giralt, S., Estey, E., Albitar, M., Van Besien, K., Rondon, G., Anderlini, P., O'Brien, S., Khouri, I., Gajewski, J., Mehra, R., Claxton, D., Andersson, B., Beran, M., Przepiorka, D., Koller, C., Kornblau, S., Korbling, M., Keating, M., Kantarjian, H., and Champlin, R. Engraftment of allogenic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood, 89: 4531-4536, 1997.
3. Slavin, S., Nagler, A., Naparstek, E., Kapelushnik, Y., Aker, M., Cividalli, G., Varadi, G., Kirschbaum, M., Ackerstein, A., Samuel, S., Amar, A., Brautbar, C., Ben-Tal, O., Eldor, A., and Or, R. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood, 91: 756-763, 1998.
4. Khouri, I. F., Keating, M., Korbling, M., Przepiorka, D., Anderlini, P., O'Brien, S., Giralt, S., Ippoliti, C., Von Wolff, B., Gajewski, J., Donato, M., Claxton, D., Ueno, N., Andersson, B., Gee, A., and Champlin, R. Transplant-Lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J. Clin. Oncol., 16: 2817-2824, 1998.
5. Sykes, M., Preffer, F., McAfee, S., Saidman, S. L., Weymouth, D., Andrews, D. M., Colby, C., Sackstein, R., Sachs, D. H., and Spitzer, T. R. Mixed lymphohematopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched donor-bone marrow transplantation. Lancet, 353: 1755-1759, 1999.
6. McSweeney, P. A., Niederwieser, D., Shizuru, J. A., Sandmaier, B. M., Molina, A. J., Maloney, D. G., Chauncey, T. R., Gooley, T. A., Hegenbart, U., Nash, R. A., Radich, J., Wagner, J. L., Minor, S., Appelbaum, F. R., Bensinger, W. I., Bryant, E., Flowers, M. E. D., George, G., E., Grumet, F. C., Kiem, H-P., Torok-Storb, B., Yu, C., Blume, K. G., and Storb. R. F. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood, 97: 3390-3400, 1999.
7. Childs, R., Clave, E., Contentin, N., Jayasekera, D., Hensel, N., Leitman, S., Read, E. J., Carter, C., Bahceci, E., Young, N. S., and Barrett, A. J. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation; full donor T-cell chimerism precedes alloimmune responses. Blood, 94: 3234-3241, 1999.
8. Kottaridis, P. D., Milligan, D. W., Chopra, R., Chakraverty, R. K., Chakrabarti, S., Robinson, S., Peggs, K., Verfuerth, S., Pettengell, R., Marsh, J. C. W., Schey, S., Mahendra, P., Morgan, G. J., Hale, G., Waldmann, H., Elvira, M. C., Devereux, S., Linch, D. C., Goldstone, A., H., and Mackinnon, S. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood, 96: 2419-2425, 2000.
9. Childs, R., Chernoff, A., Contentin, N., Bahceci, E., Schrump, D., Leitman, S., Read, E. J., Tisdale, J., Dunbar, C., Linehan, W. M., Young, N. S., and Barrett, A. J. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N. Engl. J. Med., 343: 750-758, 2000.
10. Keating, M. J., Kantarjian, H., Talpaz, M., Redman, J., Koller, C., Barlogie, B., Velasquez, W., Plunkett, W., Freireich, E. J., and McCredie, K. B. Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood, 74: 19-25, 1989.
11. Seto, S., Carrera, C. J., Kubota, M., Wasson, D. B., and Carson, D. A. Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes. J. Clin. Investig., 75: 377-383, 1985.
12. Carrera, C. J., Terai, C., Lotz, M., Curd, J. G., Piro, L. D., Beutler, E., and Carson, D. Potent toxicity of 2-chlorodeoxyadenosine toward human monocytes in vitro and in vivo. J. Clin. Investig., 86: 1480-1488, 1990.
13. Liliemark, J., and Juliusson, G. On the pharmacokinetics of 2-chloro-2′-deoxyadenosine in humans. Cancer Res., 51: 5570-5572, 1991.
14. Dinndorf, P. A., Avramis, V. I., Wiersma, S., Kralio, M. D., Liu-Mares, W., Seibel, N. L., Sato, J. K., Mosher, R. B., Kelleher, J. F., and Reaman, G. H. Phase I/II study of idarubicin given with continuous infusion fludarabine followed by continuous infusion cytarabine in children with acute leukemia: a report from the Children's Cancer Group. J. Clin. Oncol., 15: 2780-2785, 1997.
15. Solal-Celigny, P., Brice, P., Brousse, N., Caspard, H., Bastion, Y., Haioun, C., Basly, A., Tilly, H., Bordessoule, D., Sebban, C., Harousseau, J. L., Morel, P., Dupas, B., Plassart, F., Vasile, N., Fort, N., and Leporrier, M. Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma. J. Clin. Oncol., 14: 514-519, 1996.
16. Morishima, Y., Morishita, Y., Tanimoto, M., Ohno, R., Saito, H., Horibe, K., Hamajima, N., Naito, K., Yamada, K., Yokomaku, S., Hirabayashi, N., Yamada, H., Nakaide, Y., Kojima, S., Minami, S., Matsuyama, K., and Kodera, Y. Low incidence of acute graft-versus-host disease by the administration of methotrexate and cyclosporine in Japanese leukemia patients after bone marrow transplantation from human leukocyte antigen compatible siblings: possible role of genetic homogeneity. Blood, 74: 2252-2256, 1989.
17. Thiede, C., Florek, M., Bornhauser, M., Ritter, M., Mohr, B., Brendel, C., Ehninger, G., and Neubauer, A. Rapid quantification of mixed chimerism using multiplex amplification of short tandem repeat markers and fluorescence detection. Bone Marrow Transplant., 23: 1055-1060, 1999.
18. Bearman, S. I., Appelbaum, F. R., Buckner, C. D., Peterson, F. B., Fisher, L. D., Clift, R. A., and Thomas, E. D. Regimen-related toxicity in patients undergoing bone marrow transplantation. J. Clin. Oncol., 6: 1562-1568, 1988.
19. Przepiorka, D., Weisdorf, D., Martin, P., Klingemann, H-G., Beatty, P., Hows, J., and Thomas, E. D. Consensus conference on acute GVHD grading. Bone Marrow Transplant., 15: 825-828, 1995.
20. Simon, R. Optimal two-stage designs for Phase II clinical trials. Control Clin. Trials, 10: 1-10, 1989.
21. Saven, A., and Piro, L. Newer purine analogues for the treatment of hairy-cell leukemia. N. Engl. J. Med., 330: 691-697, 1994.
22. Vahdat, L., Wong, E. T., Wile, M. J., Rosenblum, M., Foley, K. M., and Warrell, R. P. Therapeutic and neurotoxic effects of 2-chlorodeoxyadenosine in adults with acute myeloid leukemia. Blood, 84: 3429-3434, 1994.
23. Giralt, S., Thall, P. F., Khouri, I., Wang, X., Braunschweig, I., Ippolitti, C., Claxton, D., Donato, M., Bruton, J., Cohen, A., Davis, M., Andersson, B. S., Anderlini, P., Gajewski, J., Komblau, S., Andreeff, M., Przepiorka, D., Ueno, N. T., Molldrem, J., and Champlin, R. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood, 97: 631-637, 2001.
24. Tobinai, K., Ogura, M., Hotta, T., Kobayashi, Y., Narabayashi, M., Suzuki, R., Kinoshita, T., Kozuru, M., Uike, N., and Ohashi, Y. Phase I study of cladribine (2-chlorodeoxyadenosine) in lymphoid malignancies. Jpn. J. Clin. Oncol., 27: 146-153, 1997.
25. Bornhauser, M., Thiede, C., Schuler, U., Platzbecker, U., Freiberg-Richter, J., Helwig, A., Plettig, R., Rollig, C., Naumann, R., Kroschinski, F., Neubauer, A., and Ehninger, G. Dose-reduced conditioning for allogeneic blood stem cell transplantation: durable engraftment without antithymocyte globulin. Bone Marrow Transplant., 26: 119-125, 2000.
26. Antin, J. H., and Ferrara, J. L. M. Cytokine dysregulation and acute graft-versus-host disease. Blood, 80: 2964-2968, 1992.